Abstract
For the past century, the renin–angiotensin system (RAS) has been recognized as one of the major blood pressure-regulating systems. Angiotensin II (Ang II) is the final physiologically active product of RAS, and it works not only as a strong vasopressor but also as a promotor of tissue remodeling in various organs such as heart, arteries, and kidneys. RAS is the predominant pathway of Ang II formation in human plasma, but not in the tissues. There are several alternative pathways producing angiotensin II in human tissues, and they are involved in structural remodeling of the cardiovascular system. Proteinases such as chymase, kallikrein, cathepsin G, and elastase- 2 are probably responsible for angiotensin-converting enzyme (ACE)-independent Ang II formation in human tissues. In particular, chymase is an important Ang II-generating enzyme in the human heart. It is important to elucidate the mechanisms of the ACEindependent Ang II formation in human tissues; long-term inhibition of the local Ang II formation may become one of the strategies to prevent cardiovascular remodeling.
Keywords: Local renin–angiotensin system, angiotensin II, ACE, chymase, elastase-2, angiotensin-(1–12), cardiovascular disease.
Current Pharmaceutical Design
Title:Non-ACE Pathway-induced Angiotensin II Production
Volume: 19 Issue: 17
Author(s): Yoshinari Uehara, Shin-ichiro Miura, Eiji Yahiro and Keijiro Saku
Affiliation:
Keywords: Local renin–angiotensin system, angiotensin II, ACE, chymase, elastase-2, angiotensin-(1–12), cardiovascular disease.
Abstract: For the past century, the renin–angiotensin system (RAS) has been recognized as one of the major blood pressure-regulating systems. Angiotensin II (Ang II) is the final physiologically active product of RAS, and it works not only as a strong vasopressor but also as a promotor of tissue remodeling in various organs such as heart, arteries, and kidneys. RAS is the predominant pathway of Ang II formation in human plasma, but not in the tissues. There are several alternative pathways producing angiotensin II in human tissues, and they are involved in structural remodeling of the cardiovascular system. Proteinases such as chymase, kallikrein, cathepsin G, and elastase- 2 are probably responsible for angiotensin-converting enzyme (ACE)-independent Ang II formation in human tissues. In particular, chymase is an important Ang II-generating enzyme in the human heart. It is important to elucidate the mechanisms of the ACEindependent Ang II formation in human tissues; long-term inhibition of the local Ang II formation may become one of the strategies to prevent cardiovascular remodeling.
Export Options
About this article
Cite this article as:
Uehara Yoshinari, Miura Shin-ichiro, Yahiro Eiji and Saku Keijiro, Non-ACE Pathway-induced Angiotensin II Production, Current Pharmaceutical Design 2013; 19 (17) . https://dx.doi.org/10.2174/1381612811319170012
DOI https://dx.doi.org/10.2174/1381612811319170012 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Antioxidative Properties of Flavonoids
Current Organic Chemistry Inflammation in Ischemic Stroke Subtypes
Current Pharmaceutical Design Therapeutic Potential of Hammerhead Ribozymes in the Treatment of Hyper-Proliferative Diseases
Current Pharmaceutical Biotechnology Cyclooxygenase-2 Pathway as a Potential Therapeutic Target in Diabetic Peripheral Neuropathy
Current Drug Targets Sepsis: Links between Pathogen Sensing and Organ Damage
Current Pharmaceutical Design Reactive Oxygen Species in Vascular Wall
Cardiovascular & Hematological Disorders-Drug Targets Radix Astragali (Astragalus): Latest Advancements and Trends in Chemistry, Analysis, Pharmacology and Pharmacokinetics
Current Organic Chemistry Effects of N-Acetyl-L-Cysteine and Hyaluronic Acid on HBOC-201- Induced Systemic and Cerebral Vasoconstriction in the Rat
Current Drug Discovery Technologies Statins in Stable Angina Pectoris
Current Pharmaceutical Design Interactive Effect of Cigarette Smoking and Gene Variants for Predisposing to Cardiovascular Disease
Current Pharmaceutical Design Stroke Subtypes and their Possible Implication in Stroke Prevention Drug Strategies
Current Vascular Pharmacology Structure, Production and Function of Erythropoietin: Implications for Therapeutical Use in Cardiovascular Disease
Current Medicinal Chemistry Curcumin and its Multi-target Function Against Pain and Inflammation: An Update of Pre-clinical Data
Current Drug Targets Role of the Endocannabinoid System in the Neuroendocrine Responses to Inflammation
Current Pharmaceutical Design Clinical Studies with Paclitaxel - Eluting Stent Systems
Current Pharmaceutical Design The Role of the Thrombospondins in Healing Myocardial Infarcts
Cardiovascular & Hematological Agents in Medicinal Chemistry Heat Shock Proteins Protect Against Ischemia and Inflammation Through Multiple Mechanisms
Inflammation & Allergy - Drug Targets (Discontinued) Polymorphism in Endothelin-1 Gene: An Overview
Current Clinical Pharmacology Secondary Stroke Prevention with Antithrombotic Drugs
Current Vascular Pharmacology Endothelial Progenitors in Vascular Repair and Angiogenesis: How Many are Needed and What to do?
Cardiovascular & Hematological Disorders-Drug Targets